Research programme: synthetic cannabinoid therapeutics - Kalytera Therapeutics

Drug Profile

Research programme: synthetic cannabinoid therapeutics - Kalytera Therapeutics

Alternative Names: K 439; K-1012; K-1022; K-1032; K-1052; K-436; K-671; KAL 436; KAL 439; KAL 671; Synthetic fatty acid amide - Kalytera Therapeutics

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Kalytera Therapeutics; Tel Aviv University
  • Class Anti-inflammatories; Cannabinoids; Fatty acids; Osteoporosis therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Bone development modulators; Bone resorption factor inhibitors; Cannabinoid receptor CB1 antagonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Acne vulgaris; Respiratory distress syndrome; Sepsis; Ulcerative colitis
  • Discontinued Fracture; Osteogenesis imperfecta; Osteoporosis

Most Recent Events

  • 13 Apr 2018 Kalytera Therapeutics terminates its licence agreement with Yissum for KAL436, KAL439 and KAL671
  • 13 Apr 2018 Kalytera Therapeutics discontinued development of KAL436, KAL439 and KAL671 for bone diseases (Fracture, Osteoporosis and Osteogenesis imperfecta) in USA (unspecified route)
  • 26 Apr 2017 Kalytera Therapeutics has patents pending for the composition of matter and method of use of cannabinoid therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top